J. Seymour

H. Prince, J. Seymour, M. Wolf, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy.

J. Seymour, S. Milgrom, B. Campbell, 2022, International journal of radiation oncology, biology, physics.

The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma

F. Cavalli, R. Soffietti, C. Doglioni, 2008, British journal of haematology.

Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.

E. Campo, F. Cavalli, S. Ascani, 2007, Haematologica.

Long-term pamidronate in multiple myeloma.

J. Seymour, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas.

J. Seymour, J. Seymour, R. Gagel, 1993, Blood.

Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency

C. Cheah, J. Seymour, K. Burbury, 2013, Acta Haematologica.

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

E. Thompson, A. Roberts, A. Wei, 2021, Blood.

Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab

A. Kater, Yanwen Jiang, J. Seymour, 2020, Haematologica.

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.

Jeffrey A Jones, J. Byrd, A. Zelenetz, 2019, The Lancet. Haematology.

Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.

L. Campbell, J. Seymour, P. D'Achille, 2006, Cancer genetics and cytogenetics.

Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study.

G. Giles, R. Lindeman, S. Opat, 2022, Cancer epidemiology.

Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial.

P. Francis, M. Jefford, P. Yates, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma

S. Lade, R. Hicks, M. Hofman, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.

M. M. Mac Manus, R. Hicks, H. Prince, 2009, International journal of radiation oncology, biology, physics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

J. Melo, A. Schwarer, J. Seymour, 2013, Blood.

Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?

J. Seymour, K. Burbury, D. Westerman, 2013, Leukemia & lymphoma.

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

L. To, A. Roberts, M. Wadleigh, 2011 .

X. Extra‐nodal lymphoma in rare localisations: bone, breast and testes

J. Seymour, 2013, Hematological oncology.

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine *

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, European journal of haematology.

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, British journal of haematology.

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

P. Browett, A. Schwarer, Z. Rudzki, 2004 .

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.

M. Siddique, G. Cook, P. Ebeling, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital

L. Mileshkin, K. Thursky, J. Seymour, 2005, British Journal of Cancer.

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2011, Cancer.

Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.

S. Kirsa, R. Nation, D. Al-Badriyeh, 2013, The Journal of antimicrobial chemotherapy.

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial

G. Follows, D. Linch, Paul D. Smith, 2016, Haematologica.

and FCGR3A chemoimmunotherapy in the PRIMA study is not affected by Clinical outcome of patients with follicular lymphoma receiving

F. Jardin, G. Salles, R. Bouabdallah, 2014 .

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

F. Jardin, G. Salles, R. Bouabdallah, 2012, Blood.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR 3 A and FCGR 2 A polymorphisms

F. Jardin, G. Salles, R. Bouabdallah, 2012 .

Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma

H. Prince, A. Schwarer, D. Gill, 2010, Leukemia & lymphoma.

Clinical Trials and Observations

W. Hiddemann, M. Qumsiyeh, H. Einsele, 2005 .

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma

C. Tam, H. Prince, J. Seymour, 2006, Cancer.

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP

J. Seymour, S. Rule, R. Owen, 2005, Leukemia & lymphoma.

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies

C. Tam, H. Prince, J. Seymour, 2004, Cancer.

Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma.

J. Matthews, J. Seymour, J. Campbell, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term F ollow-Up o f a P rospective S tudy o f C ombined Modality T herapy f or S tage I -II I ndolent N on-Hodgkin's Lymphoma

Maria A. Rodriguez, L. Fuller, P. Mclaughlin, 2003 .

of patients with idiopathic pulmonary alveolar proteinosis granulocyte-macrophage colony-stimulating factor activity in the lungs High-affinity autoantibodies specifically eliminate

Y. Eishi, B. Trapnell, Yoshitsugu Yamada, 2013 .

High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.

Y. Eishi, N. Keicho, B. Trapnell, 2003, Blood.

Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.

J. Seymour, G. Ryan, D. Roos, 2006, Clinical lymphoma & myeloma.

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

E. Kimby, B. Coiffier, A. Belch, 2007 .

Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.

P. Francis, D. Rischin, H. Prince, 2002, Cytotherapy.

CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.

D. Rischin, H. Prince, P. Simmons, 2002, Cytotherapy.

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.

P. Francis, J. Zalcberg, M. Millward, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF

E. Russi, K. Nakata, J. Seymour, 2002, Thorax.

Efficacy of Granulocyte – Macrophage Colony-Stimulating Factor in Acquired Alveolar Proteinosis

A. Dunn, J. Seymour, J. Presneill, 2000 .

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

J. Seymour, 2021, Blood advances.

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

M. Keating, C. Tam, J. Seymour, 2014, Blood.

Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

R. Hicks, H. Prince, S. Harrison, 2013, British Journal of Cancer.

The infectious consequences of rituximab addition to fludarabine-containing regimens.

C. Tam, J. Seymour, 2006, Blood.

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

R. Johnstone, S. Harrison, J. Seymour, 2011, Blood.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

R. Aguiar, N. Cross, P. Rousselot, 2014, Blood.

Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy.

M. Dwyer, M. Bressel, A. Lasocki, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Utility of a clinical risk score to identify high‐risk patients with de novo acute myeloid leukaemia in first remission after high‐dose cytarabine (HiDAC) based induction chemotherapy

R. Hills, A. Wei, A. Burnett, 2013, British journal of haematology.

A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

P. Marlton, D. Gill, J. Seymour, 2008, Leukemia & lymphoma.

Legionella pneumophila mip gene sequencing to investigate a cluster of pneumonia cases

J. Seymour, J. Lanser, R. Ratcliff, 2003, Pathology.

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia

C. Tam, T. Kimber, J. Seymour, 2017, British journal of haematology.

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia

S. Stilgenbauer, A. Roberts, D. Huang, 2017, Clinical Cancer Research.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

A. Schwarer, J. Seymour, D. White, 2018, Leukemia.

Running head: Imatinib Cessation After Stable UMRD in CML

J. Melo, A. Schwarer, J. Seymour, 2017 .

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

J. Melo, A. Schwarer, J. Seymour, 2010, Leukemia.

Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1

A. López-Guillermo, E. Campo, F. Cavalli, 2004, British journal of haematology.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

C. Tam, H. Prince, S. Harrison, 2014, Annals of Hematology.

Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era.

C. Tam, J. Seymour, A. Herschtal, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab for the treatment of follicular lymphoma.

C. Cheah, J. Seymour, S. Lingaratnam, 2013, Future oncology.

What is responsible for the recent improvements in outlook for patients with follicular lymphoma?

J. Seymour, M. Bishton, 2010, Leukemia & lymphoma.

Fludarabine combinations for patients with advanced marginal zone lymphomas – best treatment option or too toxic?

J. Seymour, D. Carney, H. Miles Prince, 2009, British journal of haematology.

Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS.

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2010 .

C. Tam, H. Prince, J. Seymour, 2006, Haematologica.

13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL

D. Zannino, J. Seymour, W. Stevenson, 2015 .

Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.

R. Tsang, D. Joseph, R. Fisher, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

A. Hagemeijer, G. Mufti, B. Skikne, 2009 .

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy

J. Cerhan, G. Salles, D. Maucort-Boulch, 2017 .

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

J. Reynolds, L. Chong, P. Browett, 2012, Haematologica.

Abscopal Regressions of Lymphoma after Involved-Site Radiotherapy Confirmed by Positron Emission Tomography.

R. Hicks, M. MacManus, M. Hofman, 2020, International journal of radiation oncology, biology, physics.

Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

D. Zannino, J. Seymour, C. Sardjono, 2014 .

Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma

G. Salles, Xiaolei Zhou, C. Copley-Merriman, 2015, Hematology.

Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era?

E. Matutes, A. Polliack, J. Seymour, 2015, Leukemia & lymphoma.

Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma

H. Prince, J. Seymour, S. Peinert, 2009, Leukemia & lymphoma.

Efficacy and safety of deferasirox (Exjade) in patients with transfusion-dependent anemias : 1-year results from the large, prospective, multicenter EPIC study

M. Cappellini, Chi-kong Li, A. El‐Beshlawy, 2008 .

Effect of Deferasirox (Exjade ® ) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial

M. Cappellini, A. Taher, A. El‐Beshlawy, 2008 .

Efficacy and Safety of Deferasirox (Exjade ® ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial

M. Schmid, M. Porta, C. Rose, 2008 .

Bone Marrow Biopsy for the Initial Staging of Patients With Lymphoma : Too Soon to Toss the Trephine December

C. Cheah, J. Seymour, 2017 .

Bone marrow biopsy for the initial staging of patients with lymphoma: too soon to toss the trephine.

C. Cheah, J. Seymour, 2013, Oncology.

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

L. Sehn, J. Connors, K. Savage, 2018, European journal of cancer.

The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.

H. Prince, S. Harrison, S. Fleming, 2014, Clinical lymphoma, myeloma & leukemia.

Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?

C. Tam, J. Seymour, 2011, Leukemia & lymphoma.

Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)

W. Hiddemann, M. Dreyling, M. Gramatzki, 2005 .

Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.

G. Salles, A. López-Guillermo, R. Bouabdallah, 2010 .

Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells

H. Prince, S. Harrison, J. Seymour, 2013, Bone Marrow Transplantation.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

L. Campbell, J. Szer, I. Lewis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia☆

K. Byth, A. Morley, J. Szer, 2016, Contemporary clinical trials communications.

De novo B-cell prolymphocytic leukemia with central nervous system involvement

J. Seymour, P. Blombery, M. Tatarczuch, 2014, Leukemia & lymphoma.

Challenging historical perspectives of the 24‐h chemotherapy day: Flexible chemotherapy dose‐timing guidelines

S. Kirsa, J. Seymour, M. Alexander, 2016, Asia-Pacific journal of clinical oncology.

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome

S. Fleming, J. Seymour, K. Burbury, 2012, Leukemia & lymphoma.

Induction of hypomagnesemia during amsacrine treatment

J. Seymour, 1993, American journal of hematology.

P-276 High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML

H. Prince, D. Zannino, J. Seymour, 2013 .

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

H. Prince, J. Seymour, G. Kennedy, 2003, European journal of haematology.

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.

J. Seymour, S. Escudier, S. Escudier, 1993, Leukemia & lymphoma.

New Treatment Approaches To Indolent Non-Hodgkin's Lymphoma.

J. Seymour, 2004, Seminars in oncology.

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

J. Reynolds, A. Schwarer, Z. Rudzki, 2004 .

Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase

M. Adena, J. Seymour, R. De Abreu Lourenço, 2006, Leukemia & lymphoma.

Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.

J. Seymour, A. Bajel, S. Bassili, 2008, Leukemia research.

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

J. Reynolds, A. Schwarer, J. Seymour, 2005 .

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

S. Lade, A. Roberts, D. Huang, 2017, Blood.

Title : Clinico-pathological features and outcomes of progression of CLL on the BCL 2 inhibitor venetoclax Running Title : CLL progression on venetoclax

Surender, S. Lade, A. Roberts, 2017 .

Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options

R. Hicks, H. Prince, J. Seymour, 2005, Annals of Hematology.

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

A. Schwarer, Z. Rudzki, J. Seymour, 2008 .

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

A. Letai, M. Konopleva, H. Kantarjian, 2017 .

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

A. Nagler, I. Dufva, G. Martinelli, 2014, Blood Cancer Journal.

Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.

A. Dobrovic, J. Seymour, D. Ritchie, 2008, Blood.

The Hyper‐CVAD chemotherapy regimen has an adverse long‐term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

P. Marlton, H. Prince, D. Gill, 2006, Hematological oncology.

The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.

J. Seymour, P. Mollee, M. Wolf, 2006, Leukemia research.

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

A. Bazargan, C. Tam, H. Prince, 2016, Leukemia & lymphoma.

Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis

C. Tam, K. Thursky, J. Seymour, 2013, European journal of haematology.

The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.

H. Prince, J. Seymour, D. Ritchie, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab *

H. Prince, K. Thursky, J. Seymour, 2006, British journal of haematology.

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia

C. Tam, H. Prince, J. Seymour, 2010, Leukemia & lymphoma.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

J. Reynolds, A. Schwarer, J. Seymour, 2008 .

Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine

J. Matthews, H. Prince, J. Seymour, 2004, Leukemia.

Serological diagnosis of idiopathic pulmonary alveolar proteinosis.

S. Kudoh, J. Watanabe, Y. Inoue, 2000, American journal of respiratory and critical care medicine.

Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review

P. Marlton, J. Seymour, D. Gill, 2005, Leukemia & lymphoma.

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four

M. Gandhi, I. Lewis, R. Hicks, 2015 .

A Case of Clinical Indolent Natural Killer Cell Lineage Large Granular Lymphocytic Leukemia in a Patient with Rheumatoid Arthritis

H. Prince, J. Seymour, D. Westerman, 2003, Leukemia & lymphoma.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

David Green, Andrew D. Zelenetz, Oliver Sartor, 2009, Blood.

Central nervous system manifestations of systemic haematological malignancies and key differentials.

A. Lasocki, J. Seymour, 2022, Clinical radiology.

Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer.

P. Ebeling, K. Sanders, J. Seymour, 2015, The Journal of clinical endocrinology and metabolism.

achieve durable long-term remissions with imatinib fusion genes PDGFRB Patients with myeloid malignancies bearing

R. Aguiar, P. Rousselot, C. Dunbar, 2014 .

Concomitant FIP1L1–PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib

L. Chew, J. Seymour, K. Burbury, 2011, Leukemia & lymphoma.

Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome.

G. McArthur, J. Seymour, T. Seshadri, 2004, The New England journal of medicine.

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies

C. Tam, H. Prince, J. Seymour, 2004, American journal of hematology.

101 years of McCrae's (not Auer's) rods

J. Seymour, 2006, British journal of haematology.

Efficacy of venetoclax plus rituximab for relapsed CLL: Five-year follow-up of continuous or limited-duration therapy.

T. Kipps, A. Roberts, D. Brander, 2021, Blood.

The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution

H. Prince, J. Seymour, D. Ritchie, 2010, Expert opinion on biological therapy.

Extra‐pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte‐macrophage colony‐stimulating factor‐deficient mice

J. Seymour, 2006, Respirology.

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

W. Klapper, W. Hiddemann, K. Rufibach, 2016 .

Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas.

J. Seymour, R. Gagel, John F. Seymour, 1993, Blood.

Dosing schedule of oral valacyclovir for prevention of herpes simplex virus

H. Prince, J. Seymour, M. Slavin, 2003, Bone Marrow Transplantation.

Reduced Long-Term Survival Perturbed Neonatal Granulopoiesis , Lung Disease , Amyloidosis , and Granulocyte-Macrophage CSF Have Impaired Reproductive Capacity , Mice Lacking Both Granulocyte Colony-Stimulating Factor ( CSF ) and

C. Quilici, A. Dunn, G. Lieschke, 1997 .

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

H. Döhner, M. Minden, H. Dombret, 2014 .

Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy

J. Trapani, H. Prince, J. Seymour, 2005, The British journal of dermatology.

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

P. Marlton, H. Prince, D. Gill, 2006, Leukemia & lymphoma.

Pulmonary Alveolar Proteinosis

J. Seymour, J. Presneill, 2004, Treatments in respiratory medicine.

Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.

C. Tam, J. Seymour, D. Ritchie, 2005, Haematologica.

No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia

A. Dobrovic, J. Seymour, T. Mikeska, 2012, Leukemia & lymphoma.

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

K. Yuen, R. Johnstone, S. Harrison, 2008 .

Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia.

J. Seymour, 2020, The Lancet. Oncology.

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.

A. Roberts, C. Tam, J. Seymour, 2020, Blood.

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

T. Kipps, A. Langerak, A. Kater, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

G. Gordon, M. Hallek, S. Stilgenbauer, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

T. Kipps, G. Gordon, A. Roberts, 2017, The Lancet. Oncology.

ABT-199 for chronic lymphocytic leukemia.

J. Seymour, 2014, Clinical advances in hematology & oncology : H&O.

All is not lost – the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab

C. Tam, C. Cheah, J. Seymour, 2013, European journal of haematology.

A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.

H. Prince, S. Fleming, A. Khot, 2013, Clinical lymphoma, myeloma & leukemia.

Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone

R. Hicks, M. MacManus, S. Ng, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

L. Sehn, J. Connors, K. Savage, 2017, European journal of cancer.

myeloma reveals an adverse prognostic impact of advanced age A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple

J. Biagi, J. Zeldis, J. Seymour, 2013 .

Article Title: A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple myeloma reveals an adverse prognostic impact of advanced age Short Title: Thalidomide/interferon & myeloma

Mbbs, L. Mileshkin, J. Biagi, 2003 .

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy

R. Hicks, J. Seymour, D. Westerman, 2008, Haematologica.

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

S. Leprêtre, A. Chanan-Khan, S. Stilgenbauer, 2021 .

Dasatinib therapy can result in significant pulmonary toxicity

J. Seymour, K. Burbury, E. Januszewicz, 2015, American journal of hematology.

Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro

R. Johnstone, A. Wiegmans, J. Seymour, 2012, Leukemia.

Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail

A. Dobrovic, J. Seymour, D. Carney, 2008, BMC Biotechnology.

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.

H. Kantarjian, W. Plunkett, M. Keating, 1999, Leukemia & lymphoma.

Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study.

W. Hiddemann, A. Launonen, M. Herold, 2022, Clinical lymphoma, myeloma & leukemia.

High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma.

L. Fuller, F. Cabanillas, J. Cox, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY

H. Döhner, M. Minden, H. Dombret, 2015 .

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

I. Lewis, A. Wei, A. Enjeti, 2014 .

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

H. Döhner, M. Minden, H. Dombret, 2014 .

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

J. Szer, A. Roberts, H. Prince, 2006, Annals of Hematology.

A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.

J. Szer, S. Kirsa, L. Mileshkin, 2011, Australian health review : a publication of the Australian Hospital Association.

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

A. Berrebi, U. Jaeger, H. Döhner, 2008 .

Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL

Yanwen Jiang, W. Wierda, J. Seymour, 2022, Leukemia & lymphoma.

Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies

S. Opat, C. Tam, Jianda Hu, 2022, Advances in Therapy.

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

A. Roberts, M. Davids, A. Masud, 2021, EJHaem.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

J. Byrd, T. Kipps, M. Hallek, 2019, Blood.

Local experience with the novel human anti‐CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia

C. Cheah, J. Seymour, D. Carney, 2012, Internal medicine journal.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

L. Bullinger, H. Döhner, P. Vyas, 2018, Leukemia.

Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia

C. Tam, H. Prince, J. Seymour, 2005, Leukemia & lymphoma.

Commentary on “High-Dose Methotrexate for Isolated Central Nervous System Relapse in Patients with Testicular Non-Hodgkin's Lymphoma”

J. Seymour, B. Solomon, 2001 .

How I treat chronic lymphocytic leukemia after venetoclax.

C. Tam, J. Seymour, T. Lew, 2021, Blood.

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY

A. Langerak, A. Kater, C. Mellink, 2019, Hematological Oncology.

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

J. Reynolds, A. Wei, J. Seymour, 2018, Blood Cancer Journal.

Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.

E. Estey, R. Kurzrock, M. Keating, 1995, Leukemia.

FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY ON STAGING AND MANAGEMENT OF EARLY-STAGE FOLLICULAR NON-HODGKIN LYMPHOMA

R. Hicks, M. MacManus, J. Seymour, 2022 .

Reply to M. Sorigue et al.

R. Fisher, M. MacManus, J. Seymour, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A predictive tool for early-stage CLL.

C. Tam, J. Seymour, 2020, Blood.

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

A. Hagenbeek, G. Salles, A. López-Guillermo, 2010 .

Mantle cell lymphoma with central nervous system involvement: frequency and clinical features

H. Prince, J. Seymour, D. Ritchie, 2009, British journal of haematology.

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

G. Salles, A. López-Guillermo, B. Coiffier, 2017 .

Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia

J. Seymour, M. Slavin, K. Field, 2002, European journal of haematology.

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

M. Cappellini, Chi-kong Li, S. Thein, 2010, Haematologica.

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

S. Lade, J. Seymour, C. Stern, 2006, British Journal of Cancer.

Reproductive concerns of children and adolescents with cancer: challenges and potential solutions

J. Seymour, C. Stern, L. Orme, 2013 .

Fertility preservation in female oncology patients

J. Seymour, C. Stern, D. Gook, 2006, The Australian & New Zealand journal of obstetrics & gynaecology.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

J. Gribben, F. Cavalli, T. Habermann, 2018, The Lancet. Haematology.

Recommendations for the treatment of established fungal infections

T. Sorrell, D. Shaw, D. Ellis, 2008, Internal medicine journal.

Carbamazepine Overdose

J. Seymour, 1993, Drug safety.

Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression.

K. Thursky, J. Seymour, M. Slavin, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CLL-Specific Complications: Autoimmunity and Richter’s Transformation

J. Seymour, D. Carney, 2008 .

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies.

R. Nation, K. Thursky, J. Seymour, 2014, Diagnostic microbiology and infectious disease.

Epidemiology of invasive fungal disease in lymphoproliferative disorders

K. Thursky, J. Seymour, M. Slavin, 2015, Haematologica.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

J. Byrd, E. Montserrat, B. Cheson, 2018, Blood.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

A. Peleg, J. Seymour, D. Ritchie, 2016, The Journal of antimicrobial chemotherapy.

Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.

Ashley P Ng, K. Thursky, J. Seymour, 2005, Haematologica.

Cure of Pulmonary Rhizomucor Pusillus Infection in a Patient with Hairy-Cell Leukemia: Role of Liposomal Amphotericin B and GM-CSF

B. Ma, J. Seymour, M. Slavin, 2001, Leukemia & lymphoma.

Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphopenia

H. Prince, J. Seymour, M. Slavin, 2001, Leukemia & lymphoma.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

T. Kipps, A. Roberts, M. Davids, 2016, The New England journal of medicine.

Primary testicular lymphoma.

C. Cheah, J. Seymour, A. Wirth, 2014, Blood.

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Nicola D. Roberts, J. Seymour, T. Hughes, 2014, Blood.

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

Erinna F. Lee, W. D. Fairlie, J. Szer, 2009, Leukemia.

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing

C. Tam, E. Phillips, J. Seymour, 2019, Leukemia & lymphoma.

Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge

C. Tam, K. Thursky, J. Seymour, 2010, Leukemia & lymphoma.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

H. Dombret, G. Mufti, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of splenectomy in chronic lymphocytic leukemia.

R. Pollock, J. Cusack, M. Keating, 1997, Journal of the American College of Surgeons.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

R. Bociek, A. Chanan-Khan, K. Rai, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Hao Xiong, Yue Cui, T. Kipps, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR

L. To, A. Trickett, D. Ma, 2003, Leukemia.

The molecular pathogenesis of B‐cell non‐Hodgkin lymphoma

J. Seymour, P. Blombery, M. Wall, 2015, European journal of haematology.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

G. Gordon, M. Hallek, S. Stilgenbauer, 2016, The Lancet. Oncology.

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

T. Kipps, A. Roberts, M. Davids, 2015 .

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Susan Branford, Richard Herrmann, R. Herrmann, 2003, Blood.

Venetoclax for the treatment of mantle cell lymphoma

A. Roberts, D. Huang, C. Tam, 2019, Annals of Lymphoma.

Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry

A. Khot, J. Seymour, G. Ryland, 2018, Leukemia & lymphoma.

Therapeutic Modulators of Apoptosis and Epigenetics in Aggressive Lymphoma

M. Dickinson, J. Seymour, 2018, Springer Reference Medizin.

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

A. Roberts, C. Tam, J. Seymour, 2016, Seminars in oncology.

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms.

Daniel J. Park, D. English, G. Giles, 2016, Epigenomics.

Optimal approach for high-risk acute promyelocytic leukemia

A. Wei, J. Seymour, H. Iland, 2014, Current opinion in hematology.

Indolent lymphomas other than follicular and marginal zone lymphomas.

J. Seymour, S. Peinert, 2008, Hematology/oncology clinics of North America.

Deafness from eighth cranial nerve involvement in a patient with large‐cell transformation of mycosis fungoides

H. Prince, J. Seymour, S. Chua, 2000, European journal of haematology.

Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.

J. Biagi, J. Seymour, 2002, Blood.

C. Tam, H. Prince, J. Seymour, 2010, Leukemia.

Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.

R. Kurzrock, F. Cabanillas, F. Cabanillas, 1997, The American journal of medicine.

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.

R. Kurzrock, F. Cabanillas, M. Talpaz, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

O. Casasnovas, J. Zaucha, S. Barrington, 2014, Haematologica.

BCL2 Inhibitors: Insights into Resistance

A. Roberts, J. Seymour, M. Anderson, 2018 .

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.

Michael R. Green, L. Griffiths, M. Gandhi, 2015, The Lancet. Haematology.

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.

Terry L. Smith, L. Fuller, P. Mclaughlin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of localized low-grade follicular lymphomas.

M. MacManus, J. Seymour, 2001, Australasian radiology.

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

R. Advani, A. Roberts, S. Enschede, 2015, British journal of haematology.

The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.

E. Estey, J. Seymour, E. Estey, 1995, Leukemia & lymphoma.

Splenomegaly, eosinophilia, and pruritus: Hodgkin's disease, or...?

J. Seymour, 1997, Blood.

Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis.

A. Dunn, D. Langton, K. Nakata, 2001, American journal of respiratory and critical care medicine.

Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis.

U. Dirksen, C. Begley, S. Burdach, 1998, Blood.

Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment.

J. Seymour, R. Blum, G. Toner, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

L. Mileshkin, J. Biagi, J. Zeldis, 2003, Blood.

Mental neuropathy (Numb Chin syndrome): A harbinger of tumor progression or relapse case reports

J. Seymour, M. Rodriguez, 1993 .

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia

Anthony T Papenfuss, Piers Blombery, Yih-Chih Chan, 2017, Nature Communications.

Parathyroid hormone‐related protein in hypercalcaemia associated with haematological malignancy

T. Martin, J. Seymour, J. Seymour, 1996, British journal of haematology.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.

F. Cavalli, A. Taghian, G. Pruneri, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma

R. Kurzrock, F. Cabanillas, M. Talpaz, 1997, Annals of Internal Medicine.

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

A. Kater, J. Seymour, K. Fischer, 2021, Hematology/oncology clinics of North America.

Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older

L. Mileshkin, H. Prince, J. Seymour, 2005, Leukemia & lymphoma.

Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo‐obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion

C. Tam, M. Dickinson, J. Seymour, 2016, Internal medicine journal.

Challenges and outcomes of a randomized study of early nutrition support during autologous stem-cell transplantation.

N. Kiss, H. Prince, J. Seymour, 2014, Current oncology.

Myeloma and pregnancy: strange bedfellows?

H. Prince, S. Harrison, A. Khot, 2014, Leukemia & lymphoma.

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

C. Tam, M. Dickinson, J. Seymour, 2022, Cancers.

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.

A. Roberts, C. Tam, M. Ludford-Menting, 2020, Blood advances.

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

J. Trapani, Xiaomin Song, A. Roberts, 2020, Haematologica.

Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review.

M. Keating, R. Champlin, J. Seymour, 1994, American journal of clinical oncology.

Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator

K. Yuen, J. D. Iulio, J. Seymour, 2009, Leukemia.

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

J. Melo, G. McArthur, J. Goldman, 2007, Blood.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

R. Schlenk, A. Ganser, K. Götze, 2012, Leukemia.

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Susan Branford, J. Reynolds, N. Briggs, 2013, Blood.

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

A. Morley, J. Seymour, A. Grigg, 2011, Haematologica.

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

J. Seymour, W. Rasheed, B. Flaim, 2009, Leukemia research.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

R. Khanna, Corey Smith, M. Gandhi, 2006, Blood.

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

S. Dawson, M. Dawson, C. Pott, 2018, Nature Medicine.

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib

C. Tam, J. Seymour, K. Burbury, 2017, Leukemia & lymphoma.

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.

R. Gascoyne, R. Siebert, N. Harris, 2003, Blood.

Mantle cell lymphoma

Michael E. Williams, C. Cheah, J. Seymour, 2000, Current treatment options in oncology.

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

A. Zelenetz, M. Dyer, A. Kater, 2022, Blood advances.

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

U. Jaeger, A. Kater, M. Lefebure, 2022, Blood.

Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies.

C. Cheah, J. Seymour, Elizabeth Smyth, 2023, Cancer treatment reviews.

Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

E. Thompson, A. Roberts, D. Huang, 2020, Blood.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

L. Campbell, J. Reynolds, J. Szer, 2015, The Lancet. Haematology.

"Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission.

L. Campbell, J. Seymour, D. Westerman, 2018, Leukemia research.

A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma

V. Ganju, A. Roberts, L. Mileshkin, 2005, Clinical Cancer Research.

Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011

J. Szer, S. Kirsa, I. Davis, 2011, Internal medicine journal.

Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre

Karin M. Verspoor, L. Hall, D. Rischin, 2020, Supportive Care in Cancer.

An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009

B. Solomon, J. Szer, S. Kirsa, 2011, Internal medicine journal.

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

U. Jaeger, T. Kipps, A. Kater, 2020 .

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

A. Kater, M. Lefebure, S. Y. Kim, 2020 .

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

U. Jaeger, T. Kipps, A. Kater, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Marco Montillo, John F. Seymour, Kathryn Humphrey, 2018, The New England journal of medicine.

Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.

A. Wei, J. Seymour, H. Iland, 2014, Best practice & research. Clinical haematology.

Role of Arsenic Trioxide in Acute Promyelocytic Leukemia

J. Seymour, H. Iland, 2013, Current Treatment Options in Oncology.

Role of splenectomy in chronic lymphocytic leukemia

R. Pollock, J. Cusack, M. Keating, 1997 .

Case/control study of the role of splenectomy in chronic lymphocytic leukemia.

R. Pollock, M. Keating, J. Seymour, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary breast lymphoma.

C. Cheah, J. Seymour, B. Campbell, 2014, Cancer treatment reviews.

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

R. Bociek, F. Cavalli, S. Lade, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy

W. Hiddemann, R. Marcus, M. Herold, 2020, American journal of hematology.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.

J. Connors, K. Savage, T. Panzarella, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary skeletal muscle marginal zone lymphoma with persistent tissue tropism and PET-avidity

R. Hicks, J. Seymour, S. Gibbs, 2006, Leukemia & lymphoma.

Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B‐cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement

L. Sehn, J. Connors, K. Savage, 2016, British journal of haematology.

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

S. Opat, C. Tam, H. Prince, 2014, British Journal of Cancer.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

G. Salles, L. Xerri, P. Feugier, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement

J. Matthews, J. Seymour, M. Wolf, 2006, European journal of haematology.

Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target

G. Slack, S. Lade, M. Gandhi, 2021, British journal of haematology.

Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T‐cell lymphoproliferative disorders

J. Seymour, C. McCormack, H. Miles Prince, 2005, British journal of haematology.

Alemtuzumab: effective monotherapy for simultaneous B‐cell chronic lymphocytic leukaemia and Sézary syndrome

H. Prince, J. Seymour, S. Gibbs, 2004, European journal of haematology.

Azacitidine in adult patients with acute myeloid leukemia.

L. Pleyer, H. Döhner, H. Dombret, 2017, Critical reviews in oncology/hematology.

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

W. Novotny, P. Marlton, A. Roberts, 2019, Blood.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

G. Salles, A. López-Guillermo, L. Xerri, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

W. Wilson, V. Seshan, R. Advani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.

G. Salles, C. Chassagne‐Clément, J. Seymour, 2014, Blood.

Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis

G. Salles, A. López-Guillermo, F. Berger, 2014, British journal of haematology.

Rituximab maintenance therapy for follicular lymphoma – Authors' reply

G. Salles, A. López-Guillermo, H. Tilly, 2011, The Lancet.

Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma

C. Cheah, J. Seymour, 2013, Leukemia & lymphoma.

What is the real risk of central nervous system involvement in mantle cell lymphoma?

J. Seymour, S. Gill, 2008, Leukemia & lymphoma.

Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors.

H. Prince, J. Seymour, A. Wirth, 2001, Clinical lymphoma.

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

J. Raemaekers, M. Pfreundschuh, H. Tilly, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum MUC‐1 as a marker of disease status in multiple myeloma patients receiving thalidomide

L. Mileshkin, H. Prince, J. Seymour, 2003, British journal of haematology.

The impact of HLA class I and EBV latency‐II antigen‐specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

M. Roederer, R. Brennan, S. Burrows, 2015, Clinical and experimental immunology.

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

J. Gribben, A. Chanan-Khan, K. Rai, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Heikki Joensuu, Richard Herrmann, J. Fletcher, 2008, Clinical Cancer Research.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

L. Pleyer, R. Greil, H. Döhner, 2017, International journal of molecular sciences.

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare).

M. Davids, A. Kater, C. Nabhan, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

E. Thompson, A. Roberts, D. Huang, 2021, Blood advances.

2007: The year in review for Leukemia and Lymphoma

A. Polliack, J. Seymour, K. van Besien, 2008 .

The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review

C. Tam, H. Prince, S. Harrison, 2015, Leukemia & lymphoma.

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

P. Marlton, A. Roberts, S. Opat, 2016 .

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

M. Hallek, S. Stilgenbauer, A. Roberts, 2016 .

Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.

M. Keating, S. O'brien, J. Seymour, 1995, Leukemia & lymphoma.

Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target

F. Morabito, M. Gentile, A. Polliack, 2015, Leukemia & lymphoma.

HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY

S. Opat, C. Tam, J. Seymour, 2017 .

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

C. Tam, J. Seymour, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

T. Kipps, A. Roberts, M. Davids, 2014 .

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

T. Kipps, A. Roberts, Jennifer R. Brown, 2008 .

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

S. Y. Kim, A. Mato, J. Seymour, 2020, Haematologica.

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Dhara N. Amin, N. Johnson, M. Krem, 2023, American journal of hematology.

Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?

J. Seymour, M. Anderson, 2020, Leukemia & lymphoma.

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

A. Roberts, C. Tam, J. Seymour, 2020, Blood advances.

Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

L. Gibiansky, A. Kater, S. Girish, 2020, Leukemia & lymphoma.

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

E. Thompson, A. Roberts, D. Huang, 2019, British journal of haematology.

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

A. Iasonos, A. Stathis, A. Younes, 2018, Clinical Cancer Research.

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

A. Letai, A. Roberts, M. Davids, 2016, Blood.

5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results

R. Bociek, M. Dyer, T. Kipps, 2011 .

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

A. Roberts, S. Opat, C. Tam, 2015 .

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

G. Gordon, M. Hallek, S. Stilgenbauer, 2015 .

PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES

W. Novotny, P. Marlton, A. Roberts, 2019, HemaSphere.

A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents

S. Molica, A. Polliack, J. Seymour, 2021, Hematological oncology.

The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL

J. Seymour, 2021, Leukemia & lymphoma.

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine

L. Campbell, H. Prince, J. Seymour, 2011, European journal of haematology.

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

M. Grever, A. Saven, B. Falini, 2021, Leukemia.

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

A. Roberts, D. Huang, C. Tam, 2013 .

Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).

T. Kipps, A. Roberts, M. Davids, 2016 .

A denileukin diftitox (Ontak) associated retinopathy?

C. Harper, H. Prince, J. Ruddle, 2006, British Journal of Ophthalmology.

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A. Roberts, C. Tam, J. Seymour, 2015 .

Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study

T. Kipps, A. Roberts, M. Davids, 2015 .

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

T. Kipps, A. Roberts, M. Davids, 2014 .

The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients

A. Roberts, M. Davids, J. Pagel, 2013 .

CLL12: a positive answer to a poorly phrased question.

J. Seymour, 2022, Blood.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

M. Ziepert, N. Schmitz, C. Flowers, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment approaches for patients with TP53-mutated mantle cell lymphoma.

C. Tam, A. Khot, J. Seymour, 2023, The Lancet. Haematology.

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers

G. Giles, V. White, M. Jefford, 2017, Supportive Care in Cancer.

T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease

C. Tam, A. Khot, M. Dickinson, 2021, Bone Marrow Transplantation.

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

S. Lade, S. Dawson, M. Dawson, 2019, Blood.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, A. Zelenetz, I. Flinn, 2022, Blood.

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

S. Lade, C. Tam, C. Cheah, 2022, Blood.

Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse.

E. Giné, M. Dreyling, C. Cheah, 2022, Blood.

Progress in primary CNS lymphoma

J. Seymour, P. O'Brien, 2009, The Lancet.

Cardiac involvement in Henoch‐Schönlein purpura

J. Seymour, M. Polizzotto, S. Gibbs, 2006, Internal medicine journal.

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

C. Flowers, P. Marlton, T. Phillips, 2020 .

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Matthew E. Ritchie, Jafar S. Jabbari, M. Ritchie, 2022, Blood.

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

S. Chevret, P. Morel, V. Leblond, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

T. Miller, T. Kipps, A. Roberts, 2013 .

Immunochemotherapy in Waldenström macroglobulinemia – still the backbone of treatment

C. Buske, J. Seymour, 2015, Leukemia & lymphoma.

Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.

C. Tam, H. Prince, J. Seymour, 2005, Clinical lymphoma & myeloma.

B-Cell Prolymphocytic Leukemia (B-PLL) and T-Cell Prolymphocytic Leukemia (T-PLL)

G. Ott, E. Hsi, J. Seymour, 2014 .

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.

W. Novotny, P. Marlton, A. Roberts, 2020 .

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial

H. Prince, S. Harrison, J. Seymour, 2014, Bone Marrow Transplantation.

Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia

J. Seymour, 2016, Annals of Hematology.

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

P. Marlton, A. Roberts, S. Opat, 2016 .

Graft versus Burkitt's Lymphoma Effect after Allogeneic Marrow Transplantation

J. Seymour, J. Seymour, A. Grigg, 2002, Leukemia & lymphoma.

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

C. Tam, J. Seymour, A. George, 2013, Leukemia & lymphoma.

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.

W. Novotny, P. Marlton, A. Roberts, 2020, Blood.

Cisplatin, fludarabine, and cytarabine

J. Szer, J. Seymour, R. Fox, 2002, Cancer.

Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A

J. Szer, J. Seymour, J. Seymour, 2007, Mycoses.

Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients

R. Hicks, K. Thursky, J. Seymour, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

L. Gibiansky, A. Kater, S. Girish, 2019, Clinical Pharmacokinetics.

Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices

J. Seymour, M. Slavin, L. Worth, 2009, Supportive Care in Cancer.

Initial staging of lymphoma with positron emission tomography and computed tomography.

M. M. Mac Manus, R. Hicks, J. Seymour, 2005, Seminars in nuclear medicine.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

J. Reynolds, J. Szer, C. Tiley, 2012, Blood.

Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set

R. Hicks, H. Prince, J. Seymour, 2008, Leukemia.

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

M. Grever, A. Saven, B. Falini, 2022, Blood cancer journal.

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

J. Reynolds, A. Wei, J. Seymour, 2018, Blood Cancer Journal.

A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia

J. Szer, I. Lewis, P. Marlton, 2014, British journal of haematology.

BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

A. Roberts, S. Opat, C. Tam, 2017 .

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

H. Prince, S. Harrison, J. Seymour, 2013, Leukemia & lymphoma.

Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015

B. Nadel, K. Tarte, R. Gascoyne, 2017, Hematological oncology.

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, Critical reviews in oncology/hematology.

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

W. Hiddemann, H. Einsele, C. Pott, 2006 .

Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.

R. Hicks, J. Seymour, J. Turner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

I. Lewis, P. Marlton, D. Zannino, 2013 .

A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma

H. Prince, J. Seymour, D. Westerman, 2005, Leukemia & lymphoma.

Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes

K. Thursky, J. Seymour, T. Spelman, 2017, Leukemia & lymphoma.

Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate-chemotherapy

J. Seymour, D. Ritchie, K. Herbert, 2011, Leukemia & lymphoma.

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant‐eligible patients with previously untreated mantle cell lymphoma

S. Opat, C. Tam, M. Gilbertson, 2019, Hematological oncology.

Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients

P. Marlton, H. Prince, J. Seymour, 2008, Annals of Hematology.

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

H. Prince, S. Harrison, J. Seymour, 2011, Bone Marrow Transplantation.

Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation

J. Seymour, S. Nath, 2005, Leukemia & lymphoma.

ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.

T. Kipps, A. Roberts, M. Davids, 2014 .

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial

M. Hallek, S. Stilgenbauer, A. Roberts, 2017 .

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

G. Follows, D. Linch, Paul D. Smith, 2011 .

Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma.

H. Prince, J. Seymour, P. Blombery, 2017, Journal of the National Cancer Institute.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

M. Gandhi, I. Lewis, R. Hicks, 2017, Haematologica.

Treatment of chronic myelomonocytic leukemia with azacitidine

J. Seymour, D. Westerman, M. Dickinson, 2013, Leukemia & lymphoma.

J. Seymour, D. Carney, 2010, Leukemia & lymphoma.

Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested

J. Seymour, 2012, Leukemia & lymphoma.

Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma.

L. Fuller, F. Cabanillas, J. Seymour, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?

C. Cheah, J. Seymour, 2014, Leukemia & lymphoma.

High‐dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B‐cell lymphoma

S. Opat, C. Tam, M. Gilbertson, 2017, British Journal of Haematology.

REMOVED: Safety Is the Heart of the Matter.

J. Seymour, B. Campbell, 2020, International journal of radiation oncology, biology, physics.

BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.

R. Gascoyne, G. Salles, L. Sehn, 2020, Clinical lymphoma, myeloma & leukemia.

Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade ® ) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major

M. Cappellini, A. Taher, Mohsen Saleh Elalfy, 2008 .

P129 Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670)

C. Finelli, M. Schmid, C. Rose, 2007 .

Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study

G. Giles, R. Lindeman, S. Opat, 2023, Frontiers in Nutrition.

INTERSTITIAL LUNG DISEASE | Alveolar Proteinosis

J. Seymour, J. Presneill, K. Nakata, 2006 .

All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 )

J. Reynolds, J. Szer, C. Tiley, 2012 .

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

A. Roberts, M. Davids, D. Fisher, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

E. Thompson, A. Roberts, D. Huang, 2019, Blood.

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

J. Seymour, T. Hughes, S. Branford, 2014 .

The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials

P. Butow, S. Aranda, P. Schofield, 2019, BMC Research Notes.

Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment

P. Butow, L. Cavedon, S. Aranda, 2017, JMIR mHealth and uHealth.

Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

P. Butow, P. Schofield, J. Seymour, 2014, Palliative and Supportive Care.

Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines

J. Seymour, 2013, Annals of Hematology.

Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML.

J. Reynolds, A. Schwarer, J. Seymour, 2006 .

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

H. Kantarjian, S. Verstovsek, A. Roberts, 2013 .

Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15.

S. Lade, R. Tsang, M. MacManus, 2021, European journal of cancer.

Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells

K. Subbarao, J. Crawford, E. B. Clemens, 2023, Cell Reports Medicine.

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab

H. Eve, J. Seymour, S. Rule, 2009, Leukemia & lymphoma.

Rituximab and progressive multifocal leukoencephalopathy: A report of 35 cases.

L. Gordon, C. Bennett, A. Evens, 2008 .

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

A. Alencar, C. Tam, B. Nair, 2022, Blood.

Are dynamic or fixed FDG‐PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B‐cell lymphoma undergoing autologous haematopoietic stem cell transplantation?

A. Lambertini, M. MacManus, M. Hofman, 2023, British journal of haematology.

Patient perceptions of treatment-free remission in chronic myeloid leukemia

Y. Kashima, P. Schofield, K. Gough, 2018, Leukemia & lymphoma.

therapy in acute promyelocytic leukemia (APML4) -retinoic acid, idarubicin, and IV arsenic trioxide as initial trans All-

J. Reynolds, J. Szer, C. Tiley, 2013 .

Targeting the BRAF pathway in haematological diseases

M. Dickinson, J. Seymour, A. Grigg, 2023, Internal medicine journal.

Development of a distributed international patient data registry for hairy cell leukemia

M. Grever, A. Saven, P. Zinzani, 2022, Leukemia & lymphoma.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

J. Seymour, T. Hughes, K. Burbury, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

S. Opat, C. Tam, H. Prince, 2013 .

Diffuse Large B-cell Non-Hodgkin's Lymphoma Presenting as Sister Joseph's Nodule

C. Tam, R. Hicks, J. Seymour, 2002, Leukemia & lymphoma.

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

J. Vose, R. Walgren, C. Tam, 2022, Blood.

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

M. Keegan, J. Seymour, D. Ritchie, 2007 .

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

S. Dawson, M. Dawson, C. Pott, 2018, Nature Medicine.

Validation of the German high-grade non-hodkin lymphoma study group (DSHNHL) prognostic model for CNS replapse in a large cohort of PET/CT staged patients

M. Bøgsted, H. Johnsen, T. El‐Galaly, 2015, ICML 2015.

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

A. Roberts, M. Davids, J. Pagel, 2012 .

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

H. Döhner, M. Minden, H. Dombret, 2017, BMC Cancer.

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

R. Rosenquist, E. Thompson, A. Roberts, 2019, Blood.

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

D. Zannino, J. Seymour, W. Stevenson, 2018, Haematologica.

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

A. Roberts, M. Davids, J. Pagel, 2014, Clinical advances in hematology & oncology : H&O.

Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study

G. Salles, A. López-Guillermo, R. Bouabdallah, 2011 .

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

Ashley P Ng, K. Thursky, J. Seymour, 2004 .

Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

W. Hiddemann, K. Wilms, U. Dührsen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

T. Kipps, A. Roberts, A. Masud, 2019, Blood.

Detection of NPM1 exon 12 mutations and FLT3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia

A. Dobrovic, J. Seymour, D. Carney, 2008, Journal of hematology & oncology.

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

E. Thompson, A. Roberts, C. Tam, 2022, Blood advances.

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

E. Thompson, A. Roberts, C. Tam, 2020 .

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

A. Alencar, I. Flinn, P. Zinzani, 2023, The New England journal of medicine.

Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia

J. Seymour, M. Anderson, R. Bennett, 2023, Journal of Hematology & Oncology.

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

H. Dombret, G. Mufti, P. Fenaux, 2008 .

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

D. Chihara, C. Cheah, R. Champlin, 2015 .

ABVD versus BEACOPP for Hodgkin's lymphoma.

C. Tam, J. Seymour, A. Herschtal, 2011, The New England journal of medicine.

The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.

S. Dawson, M. Dawson, C. Pott, 2016 .

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.

P. Jain, M. Dreyling, J. Seymour, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study

G. Salles, M. Fulham, H. Tilly, 2010 .

Development of neuropathy in patients (pts) with multiple myeloma (MM) treated with thalidomide (thal)-Patterns of occurrence and the role of electrophysiologic monitoring.

L. Mileshkin, H. Prince, J. Zeldis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

T. Kipps, A. Langerak, A. Kater, 2019, Blood.

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

A. Kater, Jennifer R. Brown, J. Seymour, 2019, Blood.

Detection of NPM 1 exon 12 mutations and FLT 3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia

A. Dobrovic, J. Seymour, D. Carney, 2015 .

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

S. Verstovsek, R. Mesa, J. Dean, 2013 .

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of six cases

R. Gascoyne, R. Siebert, N. Harris, 2003 .

Fast-Track Rapid Warfarin Reversal for Elective Surgery: Extending the Efficacy Profile to High-Risk Patients with Cancer

J. Seymour, B. Riedel, A. Heriot, 2015, Anaesthesia and intensive care.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

A. Berrebi, H. Döhner, G. Fingerle-Rowson, 2010, The Lancet.

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease

C. Tam, A. Khot, M. Dickinson, 2023, Leukemia & lymphoma.

Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections

T. Sorrell, J. Szer, A. Roberts, 2004, Internal medicine journal.

Approach to relapsed CLL including Richter Transformation

J. Seymour, 2023, Hematological oncology.

The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials

P. Butow, S. Aranda, P. Schofield, 2019, BMC Research Notes.

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

C. Tam, M. Dickinson, J. Seymour, 2020 .

Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1

A. López-Guillermo, E. Campo, F. Cavalli, 2022 .

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-α-resistant hairy cell leukemia: 7-year follow-up

R. Kurzrock, M. Talpaz, J. Seymour, 1997, Leukemia.

Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of central nervous system relapse with R-CHOP(-like) therapy

L. Sehn, J. Connors, M. Bøgsted, 2015, ICML 2015.

Marginal zone lymphoma: 2023 update on diagnosis and management

C. Cheah, J. Seymour, 2023, American journal of hematology.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Blood.

Hypercalcemia in acute lymphoblastic leukemia.

H. Kantarjian, J. Seymour, 1994, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Re: cure of Helicobacter pylori infection and duration of remission in low-grade gastric mucosa-associated lymphoid tissue lymphoma.

J. Seymour, 1998, Journal of the National Cancer Institute.

Bisphosphonate‐induced osteonecrosis of the jaw requires early detection and intervention

H. Prince, J. O'grady, J. Seymour, 2005, The Medical journal of Australia.

ARISING The Bundaberg Hospital scandal : the need for reform in Queensland and beyond Public reporting of individual surgeon performance 543

J. Harrison, J. McNeil, P. Myles, 2004 .

PARATHYROID HORMONE RELATED PROTEIN IN HYPERCALCAEMIA IN CLL

M. Keating, J. Seymour, 1995, British Journal of Haematology.

uorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review

C. Tam, M. Hofman, C. Cheah, 2015 .

Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

S. Dawson, M. Dawson, C. Pott, 2017 .

Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome.

P. Greenberg, G. Garcia-Manero, P. Fenaux, 2015 .

Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis

K. Kedzierska, L. Kedzierski, K. Thursky, 2023, Leukemia & lymphoma.

Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.

R. Kurzrock, J. Cortes, F. Cabanillas, 1995, Blood.

Surveillance of second cancer after previous childhood cancer treatment.

S. Mackay, J. Seymour, Sally K Ng, 2007, Australian family physician.

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

J. Gribben, F. Morschhauser, J. Seymour, 2022, Blood.

S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY

J. Gribben, W. Hiddemann, C. Buske, 2022, HemaSphere.

Liver Transplantation in an Adult With Sclerosing Cholangitis due to Multisystem Langerhans Cell Histiocytosis

P. Bhathal, J. Seymour, M. Gonzales, 2011, American Journal of Transplantation.

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study

Dhara N. Amin, C. Flowers, M. Krem, 2020 .

AMulticenter Phase II TrialofThalidomide andCelecoxib for Patients with Relapsed and RefractoryMultipleMyeloma

V. Ganju, A. Roberts, J. Zeldis, 2005 .

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

C. Flowers, P. Marlton, T. Phillips, 2021 .

P. Francis, M. Jefford, P. Yates, 2012 .

Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.

J. Seymour, S. Branford, A. Grigg, 2006 .

Patient perceptions of treatment-free remission in chronic myeloid leukemia

Y. Kashima, P. Schofield, K. Gough, 2018, Leukemia & lymphoma.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

J. Byrd, E. Montserrat, B. Cheson, 2018, Blood.

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

S. Stilgenbauer, A. Roberts, Johnathan C. Maher, 2017 .

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

I. Flinn, A. Ashkenazi, C. Cheah, 2015, The Lancet. Haematology.

Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment

P. Butow, L. Cavedon, S. Aranda, 2017, JMIR mHealth and uHealth.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

M. Ziepert, N. Schmitz, C. Flowers, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The molecular pathogenesis of B‐cell non‐Hodgkin lymphoma

J. Seymour, P. Blombery, Meaghan Wall, 2015, European journal of haematology.

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

A. Roberts, W. Wierda, S. Enschede, 2008 .

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

A. Alencar, A. Zelenetz, I. Flinn, 2023, Journal of Clinical Oncology.

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, R. Kyle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

J. Gribben, W. Hiddemann, C. Buske, 2023, HemaSphere.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

J. Cerhan, G. Salles, D. Maucort-Boulch, 2018, Blood.

Preliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman's disease

R. Hicks, J. Seymour, S. Ramdave, 2006, Leukemia and Lymphoma.

Pulmonary alveolar proteinosis: progress in the first 44 years.

J. Seymour, J. Presneill, 2002, American journal of respiratory and critical care medicine.

Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis

R. Wolfe, J. Seymour, K. Phillips, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Regression of Gastric Lymphoma with Therapy for Helicobacter pylori Infection

J. Seymour, P. Bhathal, R. P. Anderson, 1997, Annals of Internal Medicine.

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

A. Chanan-Khan, S. Stilgenbauer, A. Kater, 2023, Blood.

Pulmonary Alveolar Proteinosis

J. Seymour, J. Presneill, Koh Nakata, 2004, Clinics in chest medicine.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

J. Raemaekers, M. Pfreundschuh, H. Tilly, 2006 .

Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.

J. Seymour, 1995, The New England journal of medicine.

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

S. Lade, A. Roberts, C. Tam, 2019, Blood.